Effects of teriparatide retreatment in osteoporotic men and women.

Finkelstein JS, Wyland JJ, Leder BZ, Burnett-Bowie SM, Lee H, Jüppner H, Neer RM

The Journal of clinical endocrinology and metabolism28 Apr 2009Cited by 51 (Europe PMC)

PMID19401368PMCIDPMC2708954DOI10.1210/jc.2009-0154PepBankPUB-19401368

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In osteoporotic men and women, posterior-anterior spine BMD increased less during teriparatide retreatment than during initial treatment.
In plain wordsIn men and women with osteoporosis, spine bone density increased less during teriparatide retreatment than during initial treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePosterior-anterior spine BMD response to retreatment
Study
n: not reported in source
Comparator
First teriparatide treatment period
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Posterior-anterior spine BMD increase
12.5%
first treatment
Posterior-anterior spine BMD increase
5.2%
retreatment
Source sentences
Summary
Posterior-anterior and lateral spine BMD increased 12.5 +/- 1.5 and 16.9 +/- 1.7%, respectively, during the first 12 months of teriparatide administration and 5.2 +/- 0.8 and 6.2 +/- 1.8%, respectively, during teriparatide retreatment (P < 0.001 and P = 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Teriparatide was administered to all subjects during months 42 to 54 (phase 3).
Summary · context
We compared changes in BMD and markers of bone turnover (serum osteocalcin, N-terminal propeptide of type 1 collagen, and N-telopeptide) between phase 1 and 3 in subjects receiving teriparatide alone.
Report a problemFND-1940136801
02HumanNon-randomized trialEfficacy outcome
In osteoporotic men and women, lateral spine BMD increased less during teriparatide retreatment than during initial treatment.
In plain wordsIn men and women with osteoporosis, lateral spine bone density increased less during teriparatide retreatment than during initial treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseLateral spine BMD response to retreatment
Study
n: not reported in source
Comparator
First teriparatide treatment period
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Lateral spine BMD increase
16.9%
first treatment
Lateral spine BMD increase
6.2%
retreatment
Source sentences
Summary
Posterior-anterior and lateral spine BMD increased 12.5 +/- 1.5 and 16.9 +/- 1.7%, respectively, during the first 12 months of teriparatide administration and 5.2 +/- 0.8 and 6.2 +/- 1.8%, respectively, during teriparatide retreatment (P < 0.001 and P = 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Teriparatide was administered to all subjects during months 42 to 54 (phase 3).
Summary · context
We compared changes in BMD and markers of bone turnover (serum osteocalcin, N-terminal propeptide of type 1 collagen, and N-telopeptide) between phase 1 and 3 in subjects receiving teriparatide alone.
Report a problemFND-1940136802
03HumanNon-randomized trialActivity measurement
In osteoporotic men and women, osteocalcin increased less during teriparatide retreatment than during initial treatment.
In plain wordsIn men and women with osteoporosis, osteocalcin increased less during teriparatide retreatment than during initial treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseOsteocalcin response to retreatment
Study
n: not reported in source
Comparator
First teriparatide treatment period
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Increases in osteocalcin (P < 0.001), N-terminal propeptide of type 1 collagen (P < 0.001), and N-telopeptide (P < 0.001) were greater during the first period of teriparatide administration.
2 context sentences(design, population, supporting numbers)
Summary · context
Teriparatide was administered to all subjects during months 42 to 54 (phase 3).
Summary · context
We compared changes in BMD and markers of bone turnover (serum osteocalcin, N-terminal propeptide of type 1 collagen, and N-telopeptide) between phase 1 and 3 in subjects receiving teriparatide alone.
Report a problemFND-1940136803
04HumanNon-randomized trialActivity measurement
In osteoporotic men and women, collagen propeptide increased less during teriparatide retreatment than during initial treatment.
In plain wordsIn men and women with osteoporosis, a bone formation marker increased less during teriparatide retreatment than during initial treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseN-terminal propeptide of type 1 collagen response to retreatment
Study
n: not reported in source
Comparator
First teriparatide treatment period
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Increases in osteocalcin (P < 0.001), N-terminal propeptide of type 1 collagen (P < 0.001), and N-telopeptide (P < 0.001) were greater during the first period of teriparatide administration.
2 context sentences(design, population, supporting numbers)
Summary · context
Teriparatide was administered to all subjects during months 42 to 54 (phase 3).
Summary · context
We compared changes in BMD and markers of bone turnover (serum osteocalcin, N-terminal propeptide of type 1 collagen, and N-telopeptide) between phase 1 and 3 in subjects receiving teriparatide alone.
Report a problemFND-1940136804
05HumanNon-randomized trialActivity measurement
In osteoporotic men and women, N-telopeptide increased less during teriparatide retreatment than during initial treatment.
In plain wordsIn men and women with osteoporosis, a bone breakdown marker increased less during teriparatide retreatment than during initial treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseN-telopeptide response to retreatment
Study
n: not reported in source
Comparator
First teriparatide treatment period
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Increases in osteocalcin (P < 0.001), N-terminal propeptide of type 1 collagen (P < 0.001), and N-telopeptide (P < 0.001) were greater during the first period of teriparatide administration.
2 context sentences(design, population, supporting numbers)
Summary · context
Teriparatide was administered to all subjects during months 42 to 54 (phase 3).
Summary · context
We compared changes in BMD and markers of bone turnover (serum osteocalcin, N-terminal propeptide of type 1 collagen, and N-telopeptide) between phase 1 and 3 in subjects receiving teriparatide alone.
Report a problemFND-1940136805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT00000400

Alendronate and/or Parathyroid Hormone for Osteoporosis

Massachusetts General Hospitaln = 176Aug 1999 to Jun 2006

Osteoporosis

Trial page ClinicalTrials.govUpdated 9 Dec 2013

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.